Wall Street Zen Upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) to “Buy”

Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday, Wall Street Zen reports.

MDGL has been the topic of several other reports. HC Wainwright started coverage on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 4th. They set a “strong-buy” rating on the stock. Wolfe Research upgraded shares of Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 price target for the company in a report on Tuesday, August 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research report on Thursday, October 15th. Canaccord Genuity Group raised their price objective on shares of Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Finally, Wells Fargo & Company started coverage on shares of Madrigal Pharmaceuticals in a report on Monday, July 27th. They set an “overweight” rating and a $685.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $706.87.

Madrigal Pharmaceuticals Stock Performance

NASDAQ MDGL opened at $399.63 on Friday. Madrigal Pharmaceuticals has a one year low of $353.54 and a one year high of $615.00. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.05 and a quick ratio of 2.78. The firm has a market cap of $9.28 billion, a P/E ratio of -66.83 and a beta of -0.98. The stock’s 50-day moving average is $486.74 and its 200-day moving average is $497.41.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $2.92. Madrigal Pharmaceuticals had a negative return on equity of 27.08% and a negative net margin of 10.89%. The business had revenue of $431.27 million during the quarter, compared to analyst estimates of $404.17 million. During the same period in the previous year, the firm earned ($5.08) EPS. Sell-side analysts anticipate that Madrigal Pharmaceuticals will post -2.08 earnings per share for the current fiscal year.

Insider Transactions at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, General Counsel Shannon T. Kelley sold 1,077 shares of the company’s stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $400.00, for a total transaction of $430,800.00. Following the completion of the transaction, the general counsel owned 10,397 shares of the company’s stock, valued at $4,158,800. This represents a 9.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO William Sibold sold 6,362 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $535.59, for a total value of $3,407,423.58. Following the transaction, the chief executive officer directly owned 202,967 shares of the company’s stock, valued at approximately $108,707,095.53. This trade represents a 3.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 13,324 shares of company stock valued at $7,011,982 over the last three months. Company insiders own 17.60% of the company’s stock.

Institutional Trading of Madrigal Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in MDGL. J. Goldman & Co LP acquired a new stake in shares of Madrigal Pharmaceuticals in the second quarter valued at about $2,722,000. Royal Bank of Canada boosted its position in Madrigal Pharmaceuticals by 22.5% during the first quarter. Royal Bank of Canada now owns 12,526 shares of the biopharmaceutical company’s stock valued at $6,557,000 after purchasing an additional 2,303 shares during the last quarter. Hsbc Holdings PLC boosted its position in Madrigal Pharmaceuticals by 1,738.3% during the second quarter. Hsbc Holdings PLC now owns 20,240 shares of the biopharmaceutical company’s stock valued at $10,868,000 after purchasing an additional 19,139 shares during the last quarter. Sivik Global Healthcare LLC acquired a new position in Madrigal Pharmaceuticals during the third quarter valued at approximately $1,260,000. Finally, Legal & General Group Plc bought a new position in Madrigal Pharmaceuticals in the second quarter valued at approximately $6,630,000. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Madrigal Pharmaceuticals

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Multiple real-world studies presented at AASLD reported improvements in liver stiffness and cardiometabolic health markers among patients treated with Rezdiffra, supporting the drug’s real-world potential. Rezdiffra real-world data
• Positive Sentiment: Madrigal’s latest quarterly results beat estimates: EPS was $1.83 versus consensus of a $1.09 loss, and revenue of $431.3 million exceeded the $404.2 million estimate. Madrigal stock jumps after earnings beat
• Positive Sentiment: HC Wainwright reiterated a Strong-Buy rating and projected rising EPS through 2030; Canaccord Genuity also raised its price target to $633 and maintained a Buy rating. These forecasts point to optimism about future growth, though they are analyst expectations, not guarantees.
• Neutral Sentiment: General Counsel Shannon Kelley sold 1,077 shares for about $430,800 under a pre-arranged Rule 10b5-1 plan. Kelley retained 10,397 shares, which may temper concern about the sale.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations after Madrigal’s November 3 quarterly filing. These are investigations and investor solicitations—not findings of wrongdoing—but could create legal and reputational uncertainty. Securities investigation announcement

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania.

Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.

Madrigal’s work centers on advancing medicines for liver disease, with Rezdiffra serving as its first approved therapy.